Harnessing bioluminescence for drug discovery and epigenetic research
Harnessing bioluminescence for drug discovery and epigenetic research
复制标题
DOI：
10.3389/fddsv.2023.1249507
复制
发表时间：
2023-09
期刊：
影响因子：
--
通讯作者：
Hannah J Gleneadie;Andrew Dimond;Amanda G. Fisher
中科院分区：
文献类型：
--
作者：
Hannah J Gleneadie;Andrew Dimond;Amanda G. Fisher
自然发生的生物发光现象几十年来一直吸引着旁观者，现在正被开发为医学研究和临床前成像的有力工具。荧光素酶在遇到底物时发光，使其活性能够可视化和动态跟踪。通过将荧光素酶基因插入基因组中的特定位点，可以设计报告基因以监测其天然背景下的基因表达，并检测体内的表观遗传变化。内源性生物发光报告提供了一个高度敏感的，定量读出的基因表达，既非常适合纵向研究，并可以适用于高通量药物筛选。在这篇文章中，我们概述了生物发光报告基因在表观遗传研究中的一些应用和益处，特别关注揭示治疗遗传和表观遗传疾病的新治疗选择。
The naturally occurring phenomenon of bioluminescence has intrigued on-lookers for decades and is now being developed as a powerful tool for medical research and preclinical imaging. Luciferase enzymes emit light upon substrate encounter, enabling their activity to be visualised and dynamically tracked. By inserting luciferase genes into specific sites in the genome, it is possible to engineer reporters to monitor gene expression in its native context, and to detect epigenetic change in vivo. Endogenous bioluminescent reporters provide a highly sensitive, quantitative read-out of gene expression that is both well suited to longitudinal studies and can be adapted for high-throughput drug screens. In this article we outline some of the applications and benefits of bioluminescent reporters for epigenetic research, with a particular focus on revealing new therapeutic options for treating genetic and epigenetic disorders.